Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Aldeyra Therapeutics and AbbVie Expand Option Agreement for Reproxalap, NDA Accepted for Review by FDA
Nov 18, 2024•over 1 year ago
Contract Type
agreement
MassachusettsBiotechnologyHealth CareTherapeuticsDescription
Aldeyra Therapeutics announced the expansion of its exclusive option agreement with AbbVie Inc. The U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of dry eye disease.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months